# Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

> **NCT03249870** · PHASE2 · UNKNOWN · sponsor: **Versailles Hospital** · enrollment: 130 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)

## Interventions

- **DRUG:** Inotuzumab ozogamicin (INO)

## Key facts

- **NCT ID:** NCT03249870
- **Lead sponsor:** Versailles Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-28
- **Primary completion:** 2023-05-30
- **Final completion:** 2024-06
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03249870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03249870, "Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03249870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*